John Laterra

John Laterra, MD, PhD, is a Professor of Neurology at the Kennedy Krieger Institute, affiliated with Johns Hopkins University School of Medicine. His research is centered in the Department of Neurology, where he leads a laboratory investigating the molecular and cellular mechanisms of brain tumors, particularly glioblastoma and other primary CNS malignancies.

• Department: Department of Neurology
• Institution: Kennedy Krieger Institute
• Graduate Affiliations: Neuroscience Training Program, Pathobiology Training Program

Dr. Laterra’s research focuses on the biology of cancer stem cells in glioblastoma, exploring how transcription factors (e.g., Oct4, Sox2, KLF9), receptor tyrosine kinases (e.g., c-Met), and epigenetic mechanisms regulate tumor propagation, differentiation, and therapeutic resistance. His lab integrates molecular biology, genomics (ChIP-seq, RNA-seq), and preclinical models to uncover novel pathways and translate findings into potential therapies.

The recent publications highlight a strong trend in targeting glioblastoma stem cells through epigenetic modulation, microRNA regulation, and signaling pathway inhibition. Key themes include cellular reprogramming, stemness suppression via KLF9, integrin-mediated adhesion, and nanoparticle-based delivery of regulatory miRNAs. These studies span molecular discovery to therapeutic application, reflecting a translational research trajectory.

While no specific awards are listed, Dr. Laterra’s sustained contributions to high-impact journals such as PNAS, Oncogene, and Stem Cells indicate significant recognition in the field of neuro-oncology.

Dr. Laterra has mentored numerous graduate students and postdoctoral researchers, including PhDs and doctoral candidates in Pathobiology. His lab has produced independent scientists now in academic and industry roles. There is no mention of specific grants, but his extensive publication record suggests active funding. His laboratory operates at the intersection of basic science and experimental therapeutics, contributing to both understanding glioma biology and developing novel treatment strategies.